ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/FR-alpha
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/FR-alpha
12
trial(s) found.
NCT07851025
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (
TREVI-OC-02
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Epithelial Ovarian Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT07816666
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (
TREVI-OC-03
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Epithelial Ovarian Cancer
Fallopian tube cancer
Primary peritoneal serous carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07539311
Advanced
Phase 2
Recruiting
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers (
RAINFOL-09
)
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
Gastrointestinal cancer
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT07288177
Advanced
Phase 2
Recruiting
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer (
RAINFOL-05
)
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - South Australia - GenesisCare St Andrews Hospital
WA
6150 - Murdoch - St John of God Murdoch Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT07278336
Advanced
Phase 1
Recruiting
A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer (
M25-760
)
anti-FR-alpha antibody-drug conjugate
Ovarian cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT07218809
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (
TREVI-OC-01
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2487 - Cudgen - Tweed Valley Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07213804
Advanced
Phase 3
Recruiting
FRAmework-01
: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-VEGF monoclonal antibody
Carcinoma
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
TAS
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT07166094
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy (
RAINFOL-03
)
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
Endometrial cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - GenesisCare Campbelltown
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6027 - Joondalup - Joondalup Health Campus
NCT07059845
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer (
FLORENZA
)
anti-FR-alpha antibody-drug conjugate
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Private Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06682988
Advanced
Phase 2
Recruiting
A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment (
IMGN853-0425
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
Fallopian tube cancer
Primary peritoneal serous carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2305 - New Lambton Heights - Newcastle Private Hospital
VIC
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT05797168
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (
FONTANA
)
anti-FR-alpha antibody-drug conjugate
Endometrial cancer
Lung adenocarcinoma
Ovarian cancer
Squamous non-small-cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Recruitment Country and State
NSW (10)
VIC (9)
QLD (8)
SA (6)
WA (6)
TAS (4)
ACT (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (1)
Phase 2 (4)
Phase 3 (5)
Trial Type
Advanced (12)
Cancer Therapy Class
FR-alpha
100%
VEGF
58%
PD-1
17%
PD-1/PD-L1
17%
SMO
8%
PARP
8%
PARP1-selective
8%
Facility
3168 - Clayton - Monash Medical Centre (5)
2050 - Camperdown - Chris O'Brien Lifehouse (5)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (4)
3121 - Richmond - Epworth Freemasons Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2031 - Randwick - Prince of Wales Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
5065 - Toorak Gardens - Burnside War Memorial Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2170 - Liverpool - Liverpool Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
7000 - Hobart - ICON Cancer Care Hobart (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
6150 - Murdoch - St John of God Murdoch Hospital (1)
2217 - Kogarah - St George Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3630 - Shepparton - Goulburn Valley Health (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
6027 - Joondalup - Joondalup Health Campus (1)
2217 - Kogarah - St George Private Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4032 - Chermside - The Prince Charles Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5000 - Adelaide - Cancer Research SA (1)
Cancer Type
Cancer
Solid tumour
Gynaecological cancer
Ovarian cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Endometrial cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
Gastrointestinal cancer
Primary fallopian tube serous carcinoma
Carcinoma
Breast adenocarcinoma
Breast cancer
Cervical cancer
Colorectal cancer
HPV-related cancer
HPV16-positive cancer
Lower gastrointestinal cancer
Pancreatic cancer
Pancreatobiliary cancer
Triple-negative breast cancer
Upper gastrointestinal cancer
Viral-related cancer
Lung adenocarcinoma
Non-squamous non-small-cell lung cancer
Squamous non-small-cell lung cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy